Clinical Trials Directory

Trials / Completed

CompletedNCT00330954

Gene Expression Profiling in Type 1 Diabetes

Status
Completed
Phase
Study type
Observational
Enrollment
64 (estimated)
Sponsor
Children's Mercy Hospital Kansas City · Academic / Other
Sex
All
Age
7 Years – 14 Years
Healthy volunteers
Not accepted

Summary

One of the goals of the Kansas City Diabetes Consortium is to identify and characterize genes and their products that are associated with T1DM. Characterization of such genes and their products can aid in developing new tools for risk assessment, development of new prevention strategies and monitoring progression of disease. Study design: Descriptive, basic science pilot study. The results of this pilot study will be used to help design a much larger study to address the importance of viral response and autoimmune diabetes.

Detailed description

The hypothesis is that viral responsive genes are up-regulated prior to the onset of symptoms of Type 1 Diabetes (T1DM) and may correlate with increased expression of interferon alpha. Both genetic and environmental factors contribute to risk of development of T1DM. There are a number of conflicting reports associating viral infections and T1DM in genetically susceptible individuals and causality has not been proven. Viruses may not have a large role in the initiation of islet cell autoimmunity but more of a role in acceleration of the disease leading to overt symptoms. There are no studies describing viral responsive gene expression in these individuals.

Conditions

Timeline

Start date
2006-06-01
Completion
2008-04-01
First posted
2006-05-29
Last updated
2010-03-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00330954. Inclusion in this directory is not an endorsement.